The CRISPR/Cas9 system has been used to correct COL7A1 frameshift mutations in fibroblasts from RDEB patients [224] and to delete mutant COL7A1 exons in patient keratinocytes [225]. Here, COL7A1 is linked to recessive dystrophic epidermolysis bullosa.